$KTTA
Pasithea Therapeutics Corp. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$0.490
▼-3.30%-$0.017
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonatePasithea Therapeutics Corp. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is KTTA down today? It is at $0.490 (-3.30%), and our scanner flagged it 2 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KTTA spikes, and full due diligence on KTTA — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $KTTA 2 times in the last 30 days. Create a free account to track $KTTA, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on KTTA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KTTA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Coastlands Capital Lp Beneficial Owner (10%) | Bought (open market) | +100K 0.3% of company | added 2.7% | 3.84M | $53K at $0.530 | Jun 17, 26 |
Leahy Emer Director | Acquired (grant/award) | +33K 0.10% of company | n/a | 33K | $25K at $0.750 | Nov 28, 25 |
Dumesnil Simon Director | Bought (open market) | +33K 0.10% of company | added 100% | 36K | $25K at $0.750 | Nov 28, 25 |
Marques Tiago Officer | Bought (open market) | +33K 0.10% of company | added 83% | 73K | $25K at $0.750 | Nov 28, 25 |
Schneiderman Daniel H Officer | Acquired (grant/award) | +27K 0.08% of company | n/a | 27K | $20K at $0.750 | Nov 28, 25 |
Steinman Lawrence Director | Bought (open market) | +133K 0.4% of company | added 100% | 200K | $100K at $0.750 | Nov 28, 25 |
Marques Tiago Officer | Sold (automatic/other) | -960 | sold 2.3% | 40K | $787 at $0.820 | May 12, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on KTTA from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KTTA today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
KTTA last traded at $0.490, down 3.30% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Pasithea Therapeutics Corp. Common Stock (KTTA) is next expected to report earnings on Thursday, November 12, 2026, about 53 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The KTTA Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KTTA 2 times in the last 30 days.
KTTA (Pasithea Therapeutics Corp. Common Stock) trades on XNAS, with a market cap of about $17M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KTTA for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$KTTA discussion
Sign in to ask a question or join the discussion.